Medical Biotechnology in Germany 2021

June 29, 2021 Medical Biotechnology in Germany 2021

The German biotech landscape holds immense potential with recombinant antibodies

Dr. Frank Mathias, CEO Rentschler Biopharma SE, presented the annual industry report "Medical Biotechnology in Germany 2021 " by the Boston Consulting Group and vfa bio, as chairman of vfa bio. This year’s report focuses on on recombinant antibodies and underlines the consistent growth of the German biopharmaceutical.

The full German report can be downloaded here.

Contact Person:
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication
communications@rentschler-biopharma.com